Last June, Masayoshi Son, president of Softbank Group, established SB TEMPUS, a joint venture with Tempus AI, a U.S. healthcare technology company that collects personal health data and uses AI to analyze it to develop new drugs in collaboration with pharmaceutical companies.
The use of AI is the way for Japanese healthcare to survive…but vested interests stand in the way of the “medical fee system” and the “Medical Care Act
|NEWS
